Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Dipraglurant is a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5; Ki = 21 nM).1 It inhibits glutamate-induced calcium mobilization, inositol monophosphate (IP1) accumulation, and ERK1/2 phosphorylation in HEK293A cells expressing rat mGluR5a (pKBs = 5.83, 6.5, and 6.67, respectively). Dipraglurant increases drinking in the Vogel punished drinking task, indicating anxiolytic-like activity, in rats, decreases marble burying in mice, and reduces immobility time in the forced swim test in mice (ED50s = 7.4, 43, and ~30 mg/kg, respectively).2 It reduces chorea and dystonia scores in a macaque model of MPTP-induced Parkinson’s disease L-DOPA-induced dyskinesia (PD-LID) when administered at a dose of 30 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Detailed in vitro pharmacological characterization of clinically tested negative allosteric modulators of the metabotropic glutamate receptor 5. Mol. Pharmacol. 98(1), 49-60 (2020).
2. Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on motor and non-
3. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov. Disord. 29(8), 1074-1079 (2014).